Harvard Apparatus Regenerative Tech Files Q2 2024 10-Q
Ticker: HRGN · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 1563665
| Field | Detail |
|---|---|
| Company | Harvard Apparatus Regenerative Technology, Inc. (HRGN) |
| Form Type | 10-Q |
| Filed Date | Aug 13, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, company-update
TL;DR
Harvard Apparatus Regenerative Tech filed its Q2 10-Q. Financials and operations detailed.
AI Summary
Harvard Apparatus Regenerative Technology, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Biostage, Inc., reported its financial performance and business updates. The filing details its operations in the surgical and medical instruments sector.
Why It Matters
This filing provides investors with a quarterly update on the financial health and operational status of Harvard Apparatus Regenerative Technology, Inc., crucial for understanding its current business trajectory.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains detailed financial information and business updates, which can significantly impact investment decisions and carry inherent risks.
Key Numbers
- 01746 — ZIP Code (Business and mailing address in Holliston, MA)
- 455210462 — IRS Number (Company's IRS identification number)
Key Players & Entities
- Harvard Apparatus Regenerative Technology, Inc. (company) — Filer of the 10-Q
- Biostage, Inc. (company) — Former name of the filer
- 20240630 (date) — End of the reporting period
- 20240813 (date) — Filing date
FAQ
What is the primary business of Harvard Apparatus Regenerative Technology, Inc.?
The company operates in the Surgical & Medical Instruments & Apparatus sector, SIC code 3841.
When was the company formerly known as Biostage, Inc.?
The company's name was changed from Biostage, Inc. on March 31, 2016.
What is the fiscal year end for Harvard Apparatus Regenerative Technology, Inc.?
The company's fiscal year ends on December 31.
What is the SEC file number for this company?
The SEC file number is 001-35853.
What is the reporting period covered by this 10-Q filing?
The reporting period is for the quarter ended June 30, 2024.
Filing Stats: 4,503 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-08-13 15:10:07
Filing Documents
- form10-q.htm (10-Q) — 720KB
- ex31-1.htm (EX-31.1) — 8KB
- ex31-2.htm (EX-31.2) — 8KB
- ex32-1.htm (EX-32.1) — 4KB
- ex32-2.htm (EX-32.2) — 4KB
- 0001493152-24-031570.txt ( ) — 4234KB
- hrgn-20240630.xsd (EX-101.SCH) — 31KB
- hrgn-20240630_cal.xml (EX-101.CAL) — 49KB
- hrgn-20240630_def.xml (EX-101.DEF) — 116KB
- hrgn-20240630_lab.xml (EX-101.LAB) — 327KB
- hrgn-20240630_pre.xml (EX-101.PRE) — 254KB
- form10-q_htm.xml (XML) — 506KB
-FINANCIAL INFORMATION
PART I-FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 21 Item 4.
Controls and Procedures
Controls and Procedures 21
-OTHER INFORMATION
PART II-OTHER INFORMATION 22 Item 1.
Legal Proceedings
Legal Proceedings 22 Item 1A.
Risk Factors
Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 6. Exhibits 22
SIGNATURES
SIGNATURES 24 2 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements. HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value data) June 30, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 139 $ 432 Accounts receivable — 4 Inventory 60 50 Prepaid research and development 343 210 Prepaid expenses and other current assets 114 87 Total current assets 656 783 Property, plant and equipment, net 14 25 Right-of-use assets, net 68 48 Deferred financing costs — 544 Long-term prepaid contracts 992 1,214 Total assets $ 1,730 $ 2,614 LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY Current liabilities: Accounts payable $ 752 $ 445 Accrued and other current liabilities 700 475 Convertible debt – related party 500 — Operating lease liability 40 48 Total current liabilities 1,992 968 Operating lease liability, net of current portion 28 — Total liabilities 2,020 1,411 Commitments and contingencies (Note 7) - Stockholders' (deficit) equity: Common stock, par value $ 0.01 per share, 60,000,000 shares authorized; 14,315,091 and 13,947,324 issued and outstanding at June 30, 2024 and December 31, 2023, respectively 143 139 Additional paid-in capital 96,073 93,463 Accumulated deficit ( 96,484 ) ( 91,956 ) Accumulated other comprehensive loss ( 22 ) — Total stockholders' (deficit) equity ( 290 ) 1,646 Total liabilities and stockholders' (deficit) equity $ 1,730 $ 2,614 See accompanying notes to unaudited condensed consolidated financial statements. 3 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share data) 2024 2023 2024 2023 Three Months Ended Six Month